Prof. Karim Fizazi, Centre Oscar Lambret, France
In this video, Prof. Karim Fizazi discusses the first reported results of the PEACE-2 trial. Can the addition of taxane chemotherapy to androgen deprivation therapy (ADT) plus radiotherapy redefine the treatment standard for patients with very high-risk prostate cancer? How did the regimen impact progression-free survival and metastasis-free survival? What directions lie ahead for treatment intensification and biomarker exploration?
Watch the video for Prof. Fizazi’s full interpretation and expert insights.